CSOAI - healthcare + EU AI Act
AI in healthcare and the EU AI Act
Clinical AI is squarely in the EU AI Act's high-risk tier. Transparency duties land 2 Aug 2026; the full high-risk regime phases in by Dec 2027. Here is what applies to medical AI - and how to get ready now.
High-risk uses in your sector
- !AI for medical diagnosis, triage, or screening
- !AI components inside medical devices (MDR / IVDR overlap)
- !Patient risk-stratification and resource allocation
- !AI-driven clinical decision support
What you must do
- +Human oversight of every clinical decision
- +Data governance + bias testing across patient cohorts
- +Technical documentation, logging, and traceability
- +Transparency to patients that AI is involved
Questions, answered
Yes. AI used for medical diagnosis, triage, or as a safety component of a medical device is classified high-risk under the EU AI Act, triggering conformity, oversight, and documentation duties.
Yes. The AI Act applies alongside the Medical Device and In-Vitro Diagnostic Regulations; conformity work can be aligned but the AI-specific obligations are additional.
Transparency duties apply from 2 August 2026; stand-alone Annex III high-risk obligations phase in by 2 December 2027, and AI embedded in regulated medical devices (Annex I) by 2 August 2028, under the Digital Omnibus.
Answers from published measurement, or it refuses. Your question is typed into the lobby — nothing sends until you press Ask.
Deterministic pane commands · grounded /api/chat lane · consent checkpoint on consequential steps
